American Association for Cancer Research
Browse
10780432ccr171199-sup-182478_3_supp_4587295_p4kwq2.docx (12.56 kB)

Supplementary Figure Legends from The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome

Download (12.56 kB)
journal contribution
posted on 2023-03-31, 19:51 authored by Carmela Ricciardelli, Tina Bianco-Miotto, Shalini Jindal, Lisa M. Butler, Samuel Leung, Catriona M. McNeil, Sandra A. O'Toole, Esmaeil Ebrahimie, Ewan K.A. Millar, Andrew J. Sakko, Alexandra I. Ruiz, Sarah L. Vowler, David G. Huntsman, Stephen N. Birrell, Robert L. Sutherland, Carlo Palmieri, Theresa E. Hickey, Wayne D. Tilley

Supplementary Figure Legends

Funding

National Health and Medical Research Council

National Breast Cancer Foundation

Susan G. Komen for the Cure

NHMRC

US Department of Defense Breast Cancer Research

Cancer Institute New South Wales

Sydney Catalyst Translational Research Centre

History

ARTICLE ABSTRACT

Purpose: Consensus is lacking regarding the androgen receptor (AR) as a prognostic marker in breast cancer. The objectives of this study were to comprehensively review the literature on AR prognostication and determine optimal criteria for AR as an independent predictor of breast cancer survival.Experimental Design: AR positivity was assessed by immunostaining in two clinically validated primary breast cancer cohorts [training cohort, n = 219; validation cohort, n = 418; 77% and 79% estrogen receptor alpha (ERα) positive, respectively]. The optimal AR cut-point was determined by ROC analysis in the training cohort and applied to both cohorts.Results: AR was an independent prognostic marker of breast cancer outcome in 22 of 46 (48%) previous studies that performed multivariate analyses. Most studies used cut-points of 1% or 10% nuclear positivity. Herein, neither 1% nor 10% cut-points were robustly prognostic. ROC analysis revealed that a higher AR cut-point (78% positivity) provided optimal sensitivity and specificity to predict breast cancer survival in the training (HR, 0.41; P = 0.015) and validation (HR, 0.50; P = 0.014) cohorts. Tenfold cross-validation confirmed the robustness of this AR cut-point. Patients with ERα-positive tumors and AR positivity ≥78% had the best survival in both cohorts (P < 0.0001). Among the combined ERα-positive cases, those with comparable or higher levels of AR (AR:ERα-positivity ratio >0.87) had the best outcomes (P < 0.0001).Conclusions: This study defines an optimal AR cut-point to reliably predict breast cancer survival. Testing this cut-point in prospective cohorts is warranted for implementation of AR as a prognostic factor in the clinical management of breast cancer. Clin Cancer Res; 24(10); 2328–41. ©2018 AACR.

Usage metrics

    Clinical Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC